SOD1 and amyotrophic lateral sclerosis: Most recently, Tofersen, employing the same chemical modifications as Mipomersen and Inotersen, was approved in April 2023 for amyotrophic lateral sclerosis (ALS) associated with SOD1 gene mutations [76].